Nanodrug delivery systems in tumor immunotherapy: From immune activation to tumor reprogramming
Advanced Drug Delivery Reviews · 2026-05 · 232 · 115838
DOI: 10.1016/j.addr.2026.115838 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-05. Verfasst von Dengxuan Mao und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of pharmacy, Shanghai University of Traditional Chinese Medicine, Pudong New Area, Shanghai, 201203, China. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Drug Delivery Systems, Nanoparticle Drug Delivery System. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 235 Literaturangaben.
Abstract (Originalsprache)
Nanodrug delivery systems (NDDSs) offer distinctive advantages in tumor immunotherapy, not only by enhancing drug distribution, targeting, and bioavailability but also by actively engaging in immune regulation through multiple mechanisms. In recent years, researchers have increasingly recognized that the NDDS itself can act as a pivotal driver in immune activation, participating in the induction of immunogenic cell death (ICD), the activation of dendritic cells (DCs) and T cells, the reprogramming of immunosuppressive cell populations, and the remodeling of the tumor immune microenvironment (TIME). Various nanomaterial platforms are undergoing a functional transition from "drug carriers" to "immune amplifiers." These systems are capable of spatiotemporally orchestrating synergistic responses between innate and adaptive immunity or directly modulating immune cells through specific signaling pathways to establish durable immune memory. This review systematically summarizes the key design principles and immune-activating mechanisms of diverse nanocarriers, and discusses their prospective applications in immunotherapy, particularly in combination with other therapeutic modalities. Emerging approaches, including AI-driven strategies, as well as current challenges are also highlighted. The work aims to provide theoretical foundations and design insights for the development of intelligent, immune-driven NDDSs that can advance the next generation of precision cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of pharmacy, Shanghai University of Traditional Chinese Medicine, Pudong New Area, Shanghai, 201203, China.
- School of Pharmacy, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, 1023, New Zealand.. Electronic address: z.wu@auckland.ac.nz.
- School of pharmacy, Shanghai University of Traditional Chinese Medicine, Pudong New Area, Shanghai, 201203, China. Electronic address: npfeng@shutcm.edu.cn.
Zitieren
APA
Mao, D., Li, B., Li, J., Pan, J., Wu, Z., & Feng, N. (2026). Nanodrug delivery systems in tumor immunotherapy: From immune activation to tumor reprogramming. Advanced Drug Delivery Reviews, 232, 115838. https://doi.org/10.1016/j.addr.2026.115838
Vancouver
Mao D, Li B, Li J, Pan J, Wu Z, Feng N. Nanodrug delivery systems in tumor immunotherapy: From immune activation to tumor reprogramming. Advanced Drug Delivery Reviews. 2026;232:115838. doi:10.1016/j.addr.2026.115838
BibTeX
@article{Mao2026,
author = {Mao, Dengxuan and Li, Bingqian and Li, Jing and Pan, Jianquan and Wu, Zimei and Feng, Nianping},
title = {Nanodrug delivery systems in tumor immunotherapy: From immune activation to tumor reprogramming},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
volume = {232},
pages = {115838},
doi = {10.1016/j.addr.2026.115838}
}
EUVIMED